Cargando…
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or p...
Autores principales: | Hoever, P, Dorffner, G, Beneš, H, Penzel, T, Danker-Hopfe, H, Barbanoj, M J, Pillar, G, Saletu, B, Polo, O, Kunz, D, Zeitlhofer, J, Berg, S, Partinen, M, Bassetti, C L, Högl, B, Ebrahim, I O, Holsboer-Trachsler, E, Bengtsson, H, Peker, Y, Hemmeter, U-M, Chiossi, E, Hajak, G, Dingemanse, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370822/ https://www.ncbi.nlm.nih.gov/pubmed/22549286 http://dx.doi.org/10.1038/clpt.2011.370 |
Ejemplares similares
-
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014) -
Orexins, Sleep, and Blood Pressure
por: Sieminski, Mariusz, et al.
Publicado: (2018) -
Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013) -
The relationship between orexin levels and blood pressure changes in patients with narcolepsy
por: Sieminski, Mariusz, et al.
Publicado: (2017) -
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)